205 related articles for article (PubMed ID: 34528758)
1. Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis.
Lin L; Nong W; Luo B; Ge Y; Zeng X; Li F; Fan R; Zhang Q; Xie X
Immun Inflamm Dis; 2021 Dec; 9(4):1759-1770. PubMed ID: 34528758
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
[TBL] [Abstract][Full Text] [Related]
3. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
4. Role of a novel circulatory RNA-based biomarker panel expression in ovarian cancer.
El-Shal AS; Matboli M; Abdelaziz AM; Morsy AA; Abdelbary EH
IUBMB Life; 2019 Dec; 71(12):2031-2047. PubMed ID: 31520466
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
6. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
7. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.
Tammela J; Jungbluth AA; Qian F; Santiago D; Scanlan MJ; Keitz B; Driscoll D; Rodabaugh K; Lele S; Old LJ; Odunsi K
Cancer Immun; 2004 Oct; 4():10. PubMed ID: 15487888
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
9. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
[TBL] [Abstract][Full Text] [Related]
10. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
[TBL] [Abstract][Full Text] [Related]
11. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation.
Whitehurst AW; Xie Y; Purinton SC; Cappell KM; Swanik JT; Larson B; Girard L; Schorge JO; White MA
Cancer Res; 2010 Oct; 70(19):7652-61. PubMed ID: 20876808
[TBL] [Abstract][Full Text] [Related]
12. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of ADAM9 in ovarian cancer and its clinical significance.
Guo T; Yuan D; Lin M; Zhu D; Xu N; Wang J
J Clin Lab Anal; 2020 Apr; 34(4):e23136. PubMed ID: 31793719
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.
Xu Y; Wang C; Zhang Y; Jia L; Huang J
Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056
[TBL] [Abstract][Full Text] [Related]
15. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
[No Abstract] [Full Text] [Related]
16. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
17. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters.
Luo B; Yun X; Fan R; Lin YD; He SJ; Zhang QM; Mo FR; Chen F; Xiao SW; Xie XX
Int J Clin Exp Pathol; 2013; 6(12):2835-45. PubMed ID: 24294369
[TBL] [Abstract][Full Text] [Related]
18. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.
Ma R; Tang Z; Sun K; Ye X; Cheng H; Chang X; Cui H
Pathol Res Pract; 2018 Aug; 214(8):1115-1122. PubMed ID: 29921495
[TBL] [Abstract][Full Text] [Related]
19. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
